A review of the prediction of pCR after neoadjuvant therapy for rectal cancer

doi:10.3877/cma.j.issn.2095-3224.2020.05.002

Abstract

Abstract:

Hemoglobin (Hb), neutrophil-to-lymphocyte ratio (NLR), carcinoembryonic antigen (CEA), distance of tumor from the anal verge (DTAV), tumor length (TL), clinical TNM staging (cTNM), imaging examination measures (MRI, PET-CT, rectal ultrasound, enteroscopy), parameters of neoadjuvant therapy (protocol, radiotherapy dose, time interval between neoadjuvant treatment and surgery) and from genetic/molecular features have been reported to predict pathological complete response (pCR) recently. The predictive value of the CEA, TL, and relevant parameters of neoadjuvant therapy is more stable and valuable. Examination methods such as MRI, PET-CT, endoscopy are also important ways to evaluate pCR. Genetic molecular characteristics is promising predictors, but further and larger prospective studies are still required. How to provide more accurate judgment can be further through multi-factor causal models as research directions.

Key words: Rectal neoplasms, Neoadjuvant therapy, Pathological complete response, Prediction

Yuheng Zou, Jianbo Liu, Xiaodong Wang, Li Li. A review of the prediction of pCR after neoadjuvant therapy for rectal cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2020, 09(05): 440-446.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2020.05.002

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2020/V09/I05/440

References 50

[1]	Benson AB, Venook AP, Al-Hawary MM, et al. Rectal cancer, version 2.2018, NCCN clinical practice guidelines in oncology [J]. J Natl Compr Canc Netw, 2018, 16(7): 874-901.
[2]	Du B, Wang X, Wu D, et al. MicroRNA expression profiles identify biomarkers for predicting the response to chemoradiotherapy in rectal cancer [J]. Mol Med Rep, 2018, 18(2): 1909-1916.
[3]	Kheirelseid EA, Miller N, Chang KH, et al. miRNA expressions in rectal cancer as predictors of response to neoadjuvant chemoradiation therapy [J]. Int J Colorectal Dis, 2013, 28(2): 247-260.
[4]	Martinez-Useros J, Moreno I, Fernandez-Acenero MJ, et al. The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer [J]. BMC Cancer, 2018, 18(1): 144.
[5]	Peng H, You K, Zhang R, et al. Predictive value of APAF-1 and COX-2 expression in pathologic complete response to neoadjuvant chemoradiotherapy for patients with locally advanced rectal adenocarcinoma [J]. Oncotarget, 2016, 7(23): 35233-35240.
[6]	Kundel Y, Nasser NJ, Rath-Wolfson L, et al. Molecular predictors of response to neoadjuvant chemoradiation for rectal cancer [J]. Am J Clin Oncol, 2018, 41(6): 613-618.
[7]	Yu J, Lee SH, Jeung TS, et al. Expression of vascular endothelial growth factor as a predictor of complete response for preoperative chemoradiotherapy in rectal cancer [J]. Medicine (Baltimore), 2019, 98(26): e16190.
[8]	Nelson B, Carter JV, Eichenberger MR, et al. Genetic polymorphisms in 5-Fluorouracil-related enzymes predict pathologic response after neoadjuvant chemoradiation for rectal cancer [J]. Surgery, 2016, 160(5): 1326-1332.
[9]	Chow OS, Kuk D, Keskin M, et al. KRAS and combined KRAS/TP53 mutations in locally advanced rectal cancer are independently associated with decreased response to neoadjuvant therapy [J]. Ann Surg Oncol, 2016, 23(8): 2548-2555.
[10]	Hasegawa S.,Goto S, Matsumoto T, et al. A multicenter phase 2 study on the feasibility and efficacy of neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer [J]. Ann Surg Oncol, 2017, 24(12): 3587-3595.
[11]	Sun PL, Li B, Ye QF. Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase II study [J]. Int J Colorectal Dis, 2012, 27(10): 1325-1332.
[12]	Sebio A, Salazar J, Paez D, et al. EGFR ligands and DNA repair genes: genomic predictors of complete response after capecitabine-based chemoradiotherapy in locally advanced rectal cancer [J]. Pharmacogenomics J, 2015, 15(1): 77-83.
[13]	Hodek M, Sirak I, Ferko A, et al. Neoadjuvant chemoradiotherapy of rectal carcinoma : Baseline hematologic parameters influencing outcomes [J]. Strahlenther Onkol, 2016, 192(9): 632-640.
[14]	Runau F, Collins A, Fenech GA, et al. A single institution's long-term follow-up of patients with pathological complete response in locally advanced rectal adenocarcinoma following neoadjuvant chemoradiotherapy [J]. Int J Colorectal Dis, 2017, 32(3): 341-348.
[15]	Krauthamer M, Rouvinov K, Ariad S, et al. A study of inflammation-based predictors of tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer [J]. Oncology, 2013, 85(1): 27-32.
[16]	van der Sluis FJ, van Westreenen HL, van Etten B, et al. Pretreatment identification of patients likely to have pathologic complete response after neoadjuvant chemoradiotherapy for rectal cancer [J]. Int J Colorectal Dis, 2018, 33(2): 149-157.
[17]	Peng J, Lin J, Qiu M, et al. Clinical factors of post-chemoradiotherapy as valuable indicators for pathological complete response in locally advanced rectal cancer [J]. Clinics (Sao Paulo, Brazil), 2016, 71(8): 449-454.
[18]	Kim TG, Park W, Kim H, et al. Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in rectal cancer patients following neoadjuvant chemoradiotherapy [J]. Tumori, 2019, 105(5): 434-440.
[19]	Lee SY, Kim CH, Kim YJ, et al. Obesity as an independent predictive factor for pathologic complete response after neoadjuvant chemoradiation in rectal cancer [J]. Ann Surg Treat Res, 2019, 96(3): 116-122.
[20]	Wallin U, Rothenberger D, Lowry A, et al. CEA-a predictor for pathologic complete response after neoadjuvant therapy for rectal cancer [J]. Dis Colon Rectum, 2013, 56(7): 859-868.
[21]	Li A, He K, Guo D, et al. Pretreatment blood biomarkers predict pathologic responses to neo-CRT in patients with locally advanced rectal cancer [J]. Future Oncology (London, England), 2019, 15(28): 3233-3242.
[22]	KaladyMF, de Campos-Lobato LF, Stocchi L, et al. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer [J]. Ann Surg, 2009, 250(4): 582-589.
[23]	Hu H, Huang J, Lan P, et al. CEA clearance pattern as a predictor of tumor response to neoadjuvant treatment in rectal cancer: a post-hoc analysis of FOWARC trial [J]. BMC cancer, 2018, 18(1): 1145.
[24]	Alexander JC, Silverman NA, Chretien PB. Effect of age and cigarette smoking on carcinoembryonic antigen levels [J]. JAMA, 1976, 235(18): 1975-1979.
[25]	Ren DL, Li J, Yu HC, et al. Nomograms for predicting pathological response to neoadjuvant treatments in patients with rectal cancer [J]. World J Gastroenterol, 2019, 25(1): 118-137.
[26]	Song J, Huang X, Chen Z, et al. Predictive value of carcinoembryonic antigen and carbohydrate antigen 19-9 related to downstaging to stage 0-I after neoadjuvant chemoradiotherapy in locally advanced rectal cancer [J]. Cancer Manag Res, 2018, 10: 3101-3108.
[27]	Peng H, Wang C, Xiao W, et al. Analysis of clinical characteristics to predict pathologic complete response for patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy [J]. Journal of Cancer, 2018, 9(15): 2687-2692.
[28]	Patel SV, Roxburgh CS, Vakiani E, et al. Distance to the anal verge is associated with pathologic complete response to neoadjuvant therapy in locally advanced rectal cancer [J]. J Surg Oncol, 2016, 114(5): 637-641.
[29]	van Stiphout RG, Lammering G, Buijsen J, et al. Development and external validation of a predictive model for pathological complete response of rectal cancer patients including sequential PET-CT imaging [J]. Radiother Oncol, 2011, 98(1): 126-133.
[30]	De Felice F, Izzo L, Musio D, et al. Clinical predictive factors of pathologic complete response in locally advanced rectal cancer [J]. Oncotarget, 2016, 7(22): 33374-33380.
[31]	Griethuysen JJMV, Lambregts DMJ, Trebeschi S, et al. Radiomics performs comparable to morphologic assessment by expert radiologists for prediction of response to neoadjuvant chemoradiotherapy on baseline staging MRI in rectal cancer [J]. Abdom Radiol (NY), 2020, 45(3): 632-643.
[32]	Napoletano M, Mazzucca D, Prosperi E, et al. Locally advanced rectal cancer: qualitative and quantitative evaluation of diffusion-weighted magnetic resonance imaging in restaging after neoadjuvant chemo-radiotherapy [J]. Abdom Radiol (NY), 2019, 44(11): 3664-3673.
[33]	Choi MH, Oh SN, Rha SE, et al. Diffusion-weighted imaging: Apparent diffusion coefficient histogram analysis for detecting pathologic complete response to chemoradiotherapy in locally advanced rectal cancer [J]. J Magn Reson Imaging: JMRI, 2016, 44(1): 212-220.
[34]	De Felice F, Magnante AL, Musio D, et al. Diffusion-weighted magnetic resonance imaging in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy [J]. Euro J Surg Oncol: the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2017, 43(7): 1324-1329.
[35]	Koo PJ, Kim SJ, Chang S, et al. Interim fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography to predict pathologic response to preoperative chemoradiotherapy and prognosis in patients with locally advanced rectal cancer [J]. Clin Colorectal Cancer, 2016, 15(4): e213-e219.
[36]	Park J, Chang KJ, Seo YS, et al. Tumor SUVmax normalized to liver uptake on (18)F-FDG PET/CT predicts the pathologic complete response after neoadjuvant chemoradiotherapy in locally advanced rectal cancer [J]. Nuclear Medicine and Molecular Imaging, 2014, 48(4): 295-302.
[37]	van der Sande ME, Maas M, Melenhorst J, et al. Predictive value of endoscopic features for a complete response after chemoradiotherapy for rectal cancer [J]. Ann Surg, 2019.
[38]	Kawai K, Ishihara S, Nozawa H, et al. Prediction of pathological complete response using endoscopic findings and outcomes of patients who underwent watchful waiting after chemoradiotherapy for rectal cancer [J]. Dis Colon Rectum, 2017, 60(4): 368-375.
[39]	Liu S, Zhong GX, Zhou WX, et al. Can endorectal ultrasound, mri, and mucosa integrity accurately predict the complete response for mid-low rectal cancer after preoperative chemoradiation? A prospective observational study from a single medical center [J]. Dis Colon Rectum, 2018, 61(8): 903-910.
[40]	Li N, Dou L, Zhang Y, et al. Use of sequential endorectal US to predict the tumor response of preoperative chemoradiotherapy in rectal cancer [J]. Gastrointest Endosc, 2017, 85(3): 669-674.
[41]	Deng Y, Chi P, Lan P, et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: Initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase III trial [J]. J Clin Oncol, 2016, 34(27): 3300-3307.
[42]	Hall MD, Schultheiss TE, Smith DD, et al. Effect of increasing radiation dose on pathologic complete response in rectal cancer patients treated with neoadjuvant chemoradiation therapy [J]. Acta Oncol, 2016, 55(12): 1392-1399.
[43]	Al-Sukhni E, Attwood K, Mattson DM, et al. Predictors of pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer [J]. Ann Surg Oncol, 2016, 23(4): 1177-1186.
[44]	Wiltshire KL, Ward IG, Swallow C, et al. Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: effect of dose escalation on pathologic complete response, local recurrence-free survival, disease-free survival, and overall survival [J]. International J of Radiat Oncol Biol, Physics, 2006, 64(3): 709-716.
[45]	Bujko K, Wyrwicz L, Rutkowski A, et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5×5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study [J]. Ann Oncol, 2016, 27(5): 834-842.
[46]	Lee SW, Lee JH, Lee IK, et al. The impact of surgical timing on pathologic tumor response after short course and long course preoperative chemoradiation for locally advanced rectal adenocarcinoma [J]. Cancer Res Treat: Official Journal of Korean Cancer Association, 2018, 50(3): 1039-1050.
[47]	Hoendervangers S, Couwenberg AM, Intven MPW, et al. Comparison of pathological complete response rates after neoadjuvant short-course radiotherapy or chemoradiation followed by delayed surgery in locally advanced rectal cancer [J]. Euro J Surg Oncol: the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2018, 44(7): 1013-1017.
[48]	Choi E, Kim JH, Kim OB, et al. Predictors of pathologic complete response after preoperative concurrent chemoradiotherapy of rectal cancer: a single center experience [J]. Radiat Oncol J, 2016, 34(2): 106-112.
[49]	Zeng WG, Liang JW, Wang Z, et al. Clinical parameters predicting pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer [J]. Chin J Cancer, 2015, 34(10): 468-474.
[50]	Lefevre JH, Mineur L, Kotti S, et al. Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: A multicenter, randomized, controlled trial (GRECCAR-6) [J]. J Clin Oncol, 2016, 34(31): 3773-3780.

Please choose a citation manager

Content to export